A. Compston and A. Coles, Multiple sclerosis. Lancet, pp.1502-1519, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00996686

C. Confavreux and S. Vukusic, Natural history of multiple sclerosis: a unifying concept, Brain, vol.129, issue.3, pp.606-622, 2006.
DOI : 10.1093/brain/114.6.2437

E. Havrdova, S. Galetta, M. Hutchinson, D. Stefoski, D. Bates et al., Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study, The Lancet Neurology, vol.8, issue.3, pp.254-60, 2009.
DOI : 10.1016/S1474-4422(09)70021-3

L. Kappos, E. Radue, O. Connor, P. Polman, C. Hohlfeld et al., A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis, New England Journal of Medicine, vol.362, issue.5, pp.387-401
DOI : 10.1056/NEJMoa0909494

URL : https://hal.archives-ouvertes.fr/hal-00617764

F. Jacques and F. Lublin, Defining the clinical course of multiple sclerosis: The 2013 revisions, Neurology, vol.84, issue.9, p.963, 2015.
DOI : 10.1212/01.wnl.0000462309.76486.c5

D. Rotstein, B. Healy, M. Malik, T. Chitnis, and H. Weiner, Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort, JAMA Neurology, vol.72, issue.2, pp.152-160, 2015.
DOI : 10.1001/jamaneurol.2014.3537

J. Kurtzke, Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS), Neurology, vol.33, issue.11, pp.1444-52, 1983.
DOI : 10.1212/WNL.33.11.1444

S. Rao, G. Leo, L. Ellington, T. Nauertz, L. Bernardin et al., Cognitive dysfunction in multiple sclerosis.: II. Impact on employment and social functioning, Neurology, vol.41, issue.5, pp.692-698, 1991.
DOI : 10.1212/WNL.41.5.692

C. Polman, S. Reingold, G. Edan, M. Filippi, H. Hartung et al., Diagnostic criteria for multiple sclerosis: 2005 revisions to the ???McDonald Criteria???, Annals of Neurology, vol.6, issue.6, pp.840-846, 2005.
DOI : 10.1212/WNL.53.6.1184

C. Polman, S. Reingold, B. Banwell, M. Clanet, J. Cohen et al., Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria, Annals of Neurology, vol.64, issue.suppl 2, pp.292-302, 2011.
DOI : 10.1002/ana.21464

D. Leppert, R. Lindberg, L. Kappos, and S. Leib, Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis, Brain Research Reviews, vol.36, issue.2-3, pp.249-57, 2001.
DOI : 10.1016/S0165-0173(01)00101-1

S. Agrawal, L. Lau, and V. Yong, MMPs in the central nervous system: Where the good guys go bad, Seminars in Cell & Developmental Biology, vol.19, issue.1, pp.42-51, 2008.
DOI : 10.1016/j.semcdb.2007.06.003

A. Trentini, M. Manfrinato, M. Castellazzi, C. Tamborino, G. Roversi et al., TIMP-1 resistant matrix metalloproteinase-9 is the predominant serum active isoform associated with MRI activity in patients with multiple sclerosis, Multiple Sclerosis Journal, vol.2010, issue.9, 2015.
DOI : 10.1093/brain/124.9.1743

K. Fernandes, S. Brum, D. Palei, A. Sandrim, V. Guerreiro et al., Functional MMP-9 polymorphisms modulate plasma MMP-9 levels in multiple sclerosis patients, Journal of Neuroimmunology, vol.249, issue.1-2, pp.56-65, 2012.
DOI : 10.1016/j.jneuroim.2012.04.001

V. Ozenci, L. Rinaldi, N. Teleshova, D. Matusevicius, P. Kivisäkk et al., Metalloproteinases and their tissue inhibitors in multiple sclerosis, J Autoimmun, 1999.

M. Lee, J. Palace, G. Stabler, J. Ford, A. Gearing et al., Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis, Brain, vol.122, issue.2, pp.191-198, 1999.
DOI : 10.1212/WNL.46.6.1626

M. Comabella, J. Río, C. Espejo, R. De-villa, M. Zayat et al., Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis, Clinical Immunology, vol.130, issue.2, pp.145-50, 2009.
DOI : 10.1016/j.clim.2008.09.010

A. Miller, L. Glass-marmor, M. Abraham, I. Grossman, S. Shapiro et al., Bio-markers of disease activity and response to therapy in multiple sclerosis, Clinical Neurology and Neurosurgery, vol.106, issue.3, pp.249-54, 2004.
DOI : 10.1016/j.clineuro.2004.02.008

G. Rosenberg, Matrix metalloproteinases biomarkers in multiple sclerosis, The Lancet, vol.365, issue.9467, pp.1291-1294, 2005.
DOI : 10.1016/S0140-6736(05)61008-2

E. Waubant, Biomarkers Indicative of Blood-Brain Barrier Disruption in Multiple Sclerosis, Disease Markers, vol.22, issue.4, pp.235-279, 2006.
DOI : 10.1155/2006/709869

F. Reuter, W. Zaaraoui, L. Crespy, A. Faivre, A. Rico et al., Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis, Journal of Neurology, Neurosurgery & Psychiatry, vol.82, issue.10, pp.1157-1166, 2011.
DOI : 10.1136/jnnp.2010.213744

A. Kaufman, Test Review: Wechsler, D. Manual for the Wechsler Adult Intelligence Scale, Revised, J Psychoeduc Assess, 1981.

E. Grober, H. Buschke, H. Crystal, S. Bang, and R. Dresner, Screening for dementia by memory testing, Neurology, vol.38, issue.6, pp.900-903, 1988.
DOI : 10.1212/WNL.38.6.900

A. Wiens, K. Fuller, and J. Crossen, Paced auditory serial addition test: Adult norms and moderator variables, Journal of Clinical and Experimental Neuropsychology, vol.6, issue.4, pp.473-83, 1997.
DOI : 10.1080/13854048708520046

N. Chiaravalloti and J. Deluca, Cognitive impairment in multiple sclerosis, The Lancet Neurology, vol.7, issue.12, pp.1139-51, 2008.
DOI : 10.1016/S1474-4422(08)70259-X

L. Krupp, L. Alvarez, N. Larocca, and L. Scheinberg, Fatigue in Multiple Sclerosis, Archives of Neurology, vol.45, issue.4, pp.435-442, 1988.
DOI : 10.1001/archneur.1988.00520280085020

L. Krupp and L. Elkins, Fatigue and declines in cognitive functioning in multiple sclerosis, Neurology, vol.55, issue.7, pp.934-943, 2000.
DOI : 10.1212/WNL.55.7.934

C. Schwartz, L. Coulthard-morris, and Q. Zeng, Psychosocial correlates of fatigue in multiple sclerosis, Archives of Physical Medicine and Rehabilitation, vol.77, issue.2, pp.165-70, 1996.
DOI : 10.1016/S0003-9993(96)90162-8

L. Kappos, D. Moeri, E. Radue, A. Schoetzau, K. Schweikert et al., Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis, The Lancet, vol.353, issue.9157, pp.964-973, 1999.
DOI : 10.1016/S0140-6736(98)03053-0

P. Brex, O. Ciccarelli, O. Riordan, J. Sailer, M. Thompson et al., A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis, New England Journal of Medicine, vol.346, issue.3, pp.158-64, 2002.
DOI : 10.1056/NEJMoa011341

E. Sbardella, F. Tona, N. Petsas, and P. Pantano, DTI Measurements in Multiple Sclerosis: Evaluation of Brain Damage and Clinical Implications, Multiple Sclerosis International, vol.22, issue.8, p.671730, 2013.
DOI : 10.1212/WNL.0b013e318206ca61

S. Song, S. Sun, W. Ju, S. Lin, A. Cross et al., Diffusion tensor imaging detects and differentiates axon and myelin degeneration in mouse optic nerve after retinal ischemia, NeuroImage, vol.20, issue.3, pp.1714-1736, 2003.
DOI : 10.1016/j.neuroimage.2003.07.005

M. Budde, J. Kim, H. Liang, J. Russell, A. Cross et al., diffusion tensor imaging correlates with neurological disability in a mouse model of multiple sclerosis, NMR in Biomedicine, vol.51, issue.1, pp.589-97, 2008.
DOI : 10.1212/WNL.51.1.234

S. Sun, H. Liang, R. Schmidt, A. Cross, and S. Song, Selective vulnerability of cerebral white matter in a murine model of multiple sclerosis detected using diffusion tensor imaging, Neurobiology of Disease, vol.28, issue.1, pp.30-38, 2007.
DOI : 10.1016/j.nbd.2007.06.011

S. Smith, M. Jenkinson, H. Johansen-berg, D. Rueckert, T. Nichols et al., Tract-based spatial statistics: Voxelwise analysis of multi-subject diffusion data, NeuroImage, vol.31, issue.4, pp.1487-505, 2006.
DOI : 10.1016/j.neuroimage.2006.02.024

M. Onu, A. Roceanu, U. Sboto-frankenstein, R. Bendic, E. Tarta et al., Diffusion abnormality maps in demyelinating disease: Correlations with clinical scores, European Journal of Radiology, vol.81, issue.3, pp.386-91
DOI : 10.1016/j.ejrad.2011.12.014

A. Giorgio, J. Palace, H. Johansen-berg, S. Smith, S. Ropele et al., Relationships of brain white matter microstructure with clinical and MR measures in relapsing-remitting multiple sclerosis, Journal of Magnetic Resonance Imaging, vol.130, issue.2, 2010.
DOI : 10.1212/WNL.56.7.926

N. Moll, A. Rietsch, S. Thomas, A. Ransohoff, J. Lee et al., Multiple sclerosis normal-appearing white matter: Pathology-imaging correlations, Annals of Neurology, vol.60, issue.pt 2, pp.764-73, 2011.
DOI : 10.1212/01.WNL.0000055926.69643.03

F. Tovar-moll, I. Evangelou, A. Chiu, S. Auh, C. Chen et al., Diffuse and Focal Corticospinal Tract Disease and Its Impact on Patient Disability in Multiple Sclerosis, Journal of Neuroimaging, vol.15, issue.2, 2014.
DOI : 10.1002/nbm.782

C. Jacobsen, J. Hagemeier, K. Myhr, H. Nyland, K. Lode et al., Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study, Journal of Neurology, Neurosurgery & Psychiatry, vol.33, issue.10, pp.1109-1124, 2014.
DOI : 10.1002/hbm.21279

M. Schoonheim, V. Popescu, R. Lopes, F. Wiebenga, O. Vrenken et al., Subcortical atrophy and cognition: Sex effects in multiple sclerosis, Neurology, vol.79, issue.17, pp.1754-61, 2012.
DOI : 10.1212/WNL.0b013e3182703f46

M. Sormani, D. Arnold, D. Stefano, and N. , Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis, Annals of Neurology, vol.70, issue.1, pp.43-52, 2014.
DOI : 10.1136/jnnp.70.4.494

M. Amato, E. Portaccio, and B. Goretti, Association of Neocortical Volume Changes With Cognitive Deterioration in Relapsing-Remitting Multiple Sclerosis, Archives of Neurology, vol.64, issue.8, pp.1157-61, 2007.
DOI : 10.1001/archneur.64.8.1157

C. Polman, S. Reingold, B. Banwell, M. Clanet, J. Cohen et al., Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria, Annals of Neurology, vol.64, issue.suppl 2, pp.292-302, 2011.
DOI : 10.1002/ana.21464

C. Confavreux and S. Vukusic, Natural history of multiple sclerosis: a unifying concept, Brain, vol.129, issue.3, pp.606-622, 2006.
DOI : 10.1093/brain/114.6.2437

F. Jacques and F. Lublin, Defining the clinical course of multiple sclerosis: The 2013 revisions, Neurology, vol.84, issue.9, p.963, 2015.
DOI : 10.1212/01.wnl.0000462309.76486.c5

D. Rotstein, B. Healy, M. Malik, T. Chitnis, and H. Weiner, Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort, JAMA Neurology, vol.72, issue.2, pp.152-160, 2015.
DOI : 10.1001/jamaneurol.2014.3537

C. Confavreux, S. Vukusic, and P. Adeleine, Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process, Brain, vol.126, issue.4, 2003.
DOI : 10.1093/brain/awg081

URL : https://hal.archives-ouvertes.fr/hal-00427394

F. Barkhof, The clinico-radiological paradox in multiple sclerosis revisited, Current Opinion in Neurology, vol.15, issue.3, pp.239-284, 2002.
DOI : 10.1097/00019052-200206000-00003

M. Filippi, D. Paty, L. Kappos, F. Barkhof, D. Compston et al., Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: A follow-up study, Neurology, vol.45, issue.2, pp.255-60, 1995.
DOI : 10.1212/WNL.45.2.255

L. Kappos, D. Moeri, E. Radue, A. Schoetzau, K. Schweikert et al., Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis, The Lancet, vol.353, issue.9157, pp.964-973, 1999.
DOI : 10.1016/S0140-6736(98)03053-0

P. Brex, O. Ciccarelli, O. Riordan, J. Sailer, M. Thompson et al., A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis, New England Journal of Medicine, vol.346, issue.3, pp.158-64, 2002.
DOI : 10.1056/NEJMoa011341

N. Chiaravalloti and J. Deluca, Cognitive impairment in multiple sclerosis, The Lancet Neurology, vol.7, issue.12, pp.1139-51, 2008.
DOI : 10.1016/S1474-4422(08)70259-X

S. Agrawal, L. Lau, and V. Yong, MMPs in the central nervous system: Where the good guys go bad, Seminars in Cell & Developmental Biology, vol.19, issue.1, pp.42-51, 2008.
DOI : 10.1016/j.semcdb.2007.06.003

M. Comabella, J. Río, C. Espejo, R. De-villa, M. Zayat et al., Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis, Clinical Immunology, vol.130, issue.2, pp.145-50, 2009.
DOI : 10.1016/j.clim.2008.09.010

K. Fernandes, S. Brum, D. Palei, A. Sandrim, V. Guerreiro et al., Functional MMP-9 polymorphisms modulate plasma MMP-9 levels in multiple sclerosis patients, Journal of Neuroimmunology, vol.249, issue.1-2, pp.56-65, 2012.
DOI : 10.1016/j.jneuroim.2012.04.001

M. Lee, J. Palace, G. Stabler, J. Ford, A. Gearing et al., Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis, Brain, vol.122, issue.2, pp.191-198, 1999.
DOI : 10.1212/WNL.46.6.1626

V. Ozenci, L. Rinaldi, N. Teleshova, D. Matusevicius, P. Kivisäkk et al., Metalloproteinases and their tissue inhibitors in multiple sclerosis, J Autoimmun, 1999.

G. Rosenberg, Matrix metalloproteinases biomarkers in multiple sclerosis, The Lancet, vol.365, issue.9467, pp.1291-1294, 2005.
DOI : 10.1016/S0140-6736(05)61008-2

S. Smith, M. Jenkinson, H. Johansen-berg, D. Rueckert, T. Nichols et al., Tract-based spatial statistics: Voxelwise analysis of multi-subject diffusion data, NeuroImage, vol.31, issue.4, pp.1487-505, 2006.
DOI : 10.1016/j.neuroimage.2006.02.024

S. Smith and T. Nichols, Threshold-free cluster enhancement: Addressing problems of smoothing, threshold dependence and localisation in cluster inference, NeuroImage, vol.44, issue.1, 2009.
DOI : 10.1016/j.neuroimage.2008.03.061

E. Raz, M. Cercignani, E. Sbardella, P. Totaro, C. Pozzilli et al., Gray- and White-Matter Changes 1 Year after First Clinical Episode of Multiple Sclerosis: MR Imaging, Radiology, vol.257, issue.2, pp.448-54, 2010.
DOI : 10.1148/radiol.10100626

N. Gorgoraptis, C. Wheeler-kingshott, T. Jenkins, D. Altmann, D. Miller et al., Combining tractography and cortical measures to test system-specific hypotheses in multiple sclerosis, Multiple Sclerosis Journal, vol.9, issue.5, 2010.
DOI : 10.1097/00001648-199001000-00010

A. Giorgio, J. Palace, H. Johansen-berg, S. Smith, S. Ropele et al., Relationships of brain white matter microstructure with clinical and MR measures in relapsing-remitting multiple sclerosis, Journal of Magnetic Resonance Imaging, vol.130, issue.2, pp.309-325, 2010.
DOI : 10.1212/WNL.56.7.926

F. Tovar-moll, I. Evangelou, A. Chiu, S. Auh, C. Chen et al., Diffuse and Focal Corticospinal Tract Disease and Its Impact on Patient Disability in Multiple Sclerosis, Journal of Neuroimaging, vol.15, issue.2, 2014.
DOI : 10.1002/nbm.782

K. Kern, J. Sarcona, M. Montag, B. Giesser, and N. Sicotte, Corpus callosal diffusivity predicts motor impairment in relapsing???remitting multiple sclerosis: A TBSS and tractography study, NeuroImage, vol.55, issue.3, pp.1169-77, 2011.
DOI : 10.1016/j.neuroimage.2010.10.077

S. Mesaros, M. Rocca, K. Kacar, J. Kostic, M. Copetti et al., Diffusion tensor MRI tractography and cognitive impairment in multiple sclerosis, Neurology, vol.78, issue.13, pp.969-75, 2012.
DOI : 10.1212/WNL.0b013e31824d5859

W. Tian, T. Zhu, J. Zhong, X. Liu, P. Rao et al., Progressive decline in fractional anisotropy on serial DTI examinations of the corpus callosum: a putative marker of disease activity and progression in SPMS, Neuroradiology, vol.188, issue.4, pp.287-97
DOI : 10.2214/AJR.05.2212

T. Sigal, M. Shmuel, D. Mark, H. Gil, and A. Anat, Diffusion Tensor Imaging of Corpus Callosum Integrity in Multiple Sclerosis: Correlation with Disease Variables, Journal of Neuroimaging, vol.31, issue.1, pp.33-40
DOI : 10.1002/jmri.22062

N. Evangelou, M. Esiri, S. Smith, J. Palace, and P. Matthews, Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis, Annals of Neurology, vol.36, issue.3, pp.391-396, 2000.
DOI : 10.1148/radiology.196.2.7617869

S. Song, S. Sun, W. Ju, S. Lin, A. Cross et al., Diffusion tensor imaging detects and differentiates axon and myelin degeneration in mouse optic nerve after retinal ischemia, NeuroImage, vol.20, issue.3, pp.1714-1736, 2003.
DOI : 10.1016/j.neuroimage.2003.07.005

S. Sun, H. Liang, R. Schmidt, A. Cross, and S. Song, Selective vulnerability of cerebral white matter in a murine model of multiple sclerosis detected using diffusion tensor imaging, Neurobiology of Disease, vol.28, issue.1, pp.30-38, 2007.
DOI : 10.1016/j.nbd.2007.06.011

M. Budde, J. Kim, H. Liang, J. Russell, A. Cross et al., diffusion tensor imaging correlates with neurological disability in a mouse model of multiple sclerosis, NMR in Biomedicine, vol.51, issue.1, pp.589-97, 2008.
DOI : 10.1212/WNL.51.1.234

F. Gilli, A. Bertolotto, A. Sala, F. Hoffmann, M. Capobianco et al., Neutralizing antibodies against IFN-?? in multiple sclerosis: antagonization of IFN-?? mediated suppression of MMPs, Brain, vol.127, issue.2, pp.259-68, 2004.
DOI : 10.1093/brain/awh028

E. Waubant, Biomarkers Indicative of Blood-Brain Barrier Disruption in Multiple Sclerosis, Disease Markers, vol.22, issue.4, pp.235-279, 2006.
DOI : 10.1155/2006/709869

D. Leppert, E. Waubant, M. Bürk, J. Oksenberg, and S. Hauser, Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis, Annals of Neurology, vol.1, issue.6, pp.846-52, 1996.
DOI : 10.1038/nm0395-211

A. Trentini, M. Manfrinato, M. Castellazzi, C. Tamborino, G. Roversi et al., TIMP-1 resistant matrix metalloproteinase-9 is the predominant serum active isoform associated with MRI activity in patients with multiple sclerosis, Multiple Sclerosis Journal, vol.2010, issue.9, 2015.
DOI : 10.1093/brain/124.9.1743

W. Rashid, A. Hadjiprocopis, G. Davies, C. Griffin, D. Chard et al., Longitudinal evaluation of clinically early relapsing-remitting multiple sclerosis with diffusion tensor imaging, Journal of Neurology, vol.19, issue.3, pp.390-397, 2008.
DOI : 10.1212/WNL.54.7.1421

E. Havrdova, S. Galetta, M. Hutchinson, D. Stefoski, D. Bates et al., Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study, The Lancet Neurology, vol.8, issue.3, pp.254-60, 2009.
DOI : 10.1016/S1474-4422(09)70021-3

L. Kappos, E. Radue, O. Connor, P. Polman, C. Hohlfeld et al., A placebocontrolled trial of oral fingolimod in relapsing multiple sclerosis, N Engl J Med. 2010 Feb, vol.4362, issue.5, pp.387-401
URL : https://hal.archives-ouvertes.fr/hal-00617764